Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 596 in EGFRvIII-positive glioblastoma or malignant glioma
NL-OMON48548Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2018
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of etevritamab and zeluvalimab in glioblastoma (GBM) and malignant glioma (4 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities and Safety and tolerability. Started Aug 2018; status: active, not recruiting.
02
Drugs
etevritamabzeluvalimab
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on NL-OMON48548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48548.